{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:11Z","timestamp":1792705751437,"version":"4.5.0"},"reference-count":312,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09622-9","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:28:53Z","timestamp":1744115333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical management of autoimmune liver diseases: juncture, opportunities, and challenges ahead"],"prefix":"10.1007","volume":"73","author":[{"given":"Yangfan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"issue":"3","key":"9622_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.32074\/1591-951X-241","volume":"113","author":"C Covelli","year":"2021","unstructured":"Covelli C, Sacchi D, Sarcognato S, et al. Pathology of autoimmune hepatitis. Pathologica. 2021;113(3):185\u201393.","journal-title":"Pathologica"},{"issue":"1","key":"9622_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-0039-1697617","volume":"40","author":"A Lleo","year":"2020","unstructured":"Lleo A, Leung PSC, Hirschfield GM, Gershwin EM. The pathogenesis of primary biliary cholangitis: a comprehensive review. Semin Liver Dis. 2020;40(1):34\u201348.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"9622_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. \u201cPrimary sclerosing cholangitis - a comprehensive review,\u201d (in eng). J Hepatol. 2017;67(6):1298\u2013323.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"9622_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/liv.14378","volume":"40","author":"B Engel","year":"2020","unstructured":"Engel B, Taubert R, Jaeckel E, Manns MP. The future of autoimmune liver diseases - understanding pathogenesis and improving morbidity and mortality. Liver Int. 2020;40(Suppl 1):149\u201353.","journal-title":"Liver Int"},{"issue":"6","key":"9622_CR5","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. \u201cDiagnosis and management of autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2010;51(6):2193\u2013213.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1 Suppl","key":"9622_CR6","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.1016\/j.jhep.2015.03.005","volume":"62","author":"MP Manns","year":"2015","unstructured":"Manns MP, Lohse AW, Vergani D. \u201cAutoimmune hepatitis\u2013update 2015,\u201d (in eng). J Hepatol. 2015;62(1 Suppl):S100\u201311.","journal-title":"J Hepatol"},{"key":"9622_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/978-3-319-20819-0_13","volume":"57","author":"K Senger","year":"2015","unstructured":"Senger K, Hackney J, Payandeh J, Zarrin AA. Antibody isotype switching in vertebrates. Results Probl Cell Differ. 2015;57:295\u2013324.","journal-title":"Results Probl Cell Differ"},{"key":"9622_CR8","doi-asserted-by":"crossref","unstructured":"L European Association for the Study of the, \"EASL clinical practice guidelines: autoimmune hepatitis,\" (in eng). J Hepatol. 2015;63(4):971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"9622_CR9","doi-asserted-by":"crossref","unstructured":"Primo J, Merino C, Fern\u00e1ndez J, Mol\u00e9s JR, Llorca P and Hinojosa J. \"[Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)],\" (in spa), Incidencia y prevalencia de hepatitis autoinmune en el \u00e1rea sanitaria del Hospital de Sagunto.\u00a0 Gastroenterol Hepatol. 2004;27(4)239\u201343.","DOI":"10.1157\/13059351"},{"issue":"11","key":"9622_CR10","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1080\/14656566.2021.1895747","volume":"22","author":"Y Chung","year":"2021","unstructured":"Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother. 2021;22(11):1475\u201388.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"9622_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/PAS.0000000000000395","volume":"39","author":"SM Tucker","year":"2015","unstructured":"Tucker SM, Jonas MM, Perez-Atayde AR. \u201cHyaline droplets in Kupffer cells: a novel diagnostic clue for autoimmune hepatitis,\u201d (in eng). Am J Surg Pathol. 2015;39(6):772\u20138.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"9622_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182391","volume":"12","author":"BH Kim","year":"2017","unstructured":"Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. \u201cPopulation-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea,\u201d (in eng). PLoS ONE. 2017;12(8):e0182391.","journal-title":"PLoS ONE"},{"issue":"4","key":"9622_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5223\/pghn.2018.21.4.347","volume":"21","author":"EG Harmon","year":"2018","unstructured":"Harmon EG, McConnie R, Kesavan A. Minocycline-induced autoimmune hepatitis: a rare but important cause of drug-induced autoimmune hepatitis. Pediatr Gastroenterol Hepatol Nutr. 2018;21(4):347\u201350.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"issue":"10","key":"9622_CR14","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000252","volume":"6","author":"J Grewal","year":"2019","unstructured":"Grewal J, Doan A, Hong AS, et al. Drug-induced autoimmune hepatitis from hydralazine leading to acute liver failure and liver transplantation. ACG Case Rep J. 2019;6(10):e00252.","journal-title":"ACG case reports journal"},{"issue":"6","key":"9622_CR15","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.clinre.2019.02.007","volume":"43","author":"P Muratori","year":"2019","unstructured":"Muratori P, Serio I, Lalanne C, Lenzi M. Development of autoimmune hepatitis after influenza vaccination; trigger or killer? Clin Res Hepatol Gastroenterol. 2019;43(6):e95\u20136.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"9622_CR16","doi-asserted-by":"crossref","unstructured":"Elfert KA, Qasim HM, Faisal MM, et al.\u00a0 Hepatitis E viral association with autoimmune hepatitis: a viral trigger or cross-reactivity. Case Rep Gastroenterol. 2021;15(1):115\u201322.","DOI":"10.1159\/000509494"},{"issue":"4","key":"9622_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1055\/s-2002-35705","volume":"22","author":"PT Donaldson","year":"2002","unstructured":"Donaldson PT. \u201cGenetics in autoimmune hepatitis,\u201d (in eng). Semin Liver Dis. 2002;22(4):353\u201364.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"9622_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/gut.2003.031732","volume":"53","author":"PT Donaldson","year":"2004","unstructured":"Donaldson PT. \u201cGenetics of liver disease: immunogenetics and disease pathogenesis,\u201d (in eng). Gut. 2004;53(4):599\u2013608.","journal-title":"Gut"},{"key":"9622_CR19","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1034\/j.1600-0528.2002.017401.x","volume":"174","author":"AJ Czaja","year":"2000","unstructured":"Czaja AJ, Donaldson PT. \u201cGenetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis,\u201d (in eng). Immunol Rev. 2000;174:250\u20139.","journal-title":"Immunol Rev"},{"key":"9622_CR20","doi-asserted-by":"crossref","unstructured":"Elfaramawy AA, Elhossiny RM, Abbas AA and Aziz HM. \"HLA-DRB1 as a risk factor in children with autoimmune hepatitis and its relation to hepatitis A infection,\" (in eng). Italian J Ped. 2010;36:73.","DOI":"10.1186\/1824-7288-36-73"},{"issue":"4","key":"9622_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.autrev.2010.09.024","volume":"10","author":"LC Oliveira","year":"2011","unstructured":"Oliveira LC, Porta G, Marin ML, Bittencourt PL, Kalil J, Goldberg AC. \u201cAutoimmune hepatitis, HLA and extended haplotypes,\u201d (in eng). Autoimmun Rev. 2011;10(4):189\u201393.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"9622_CR22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.gastro.2005.12.020","volume":"130","author":"Y Ma","year":"2006","unstructured":"Ma Y, Bogdanos DP, Hussain MJ, et al. \u201cPolyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2,\u201d (in eng). Gastroenterology. 2006;130(3):868\u201382.","journal-title":"Gastroenterology"},{"key":"9622_CR23","unstructured":"Underhill JA, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G and Vergani D."},{"key":"9622_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","volume":"66","author":"DG Doherty","year":"2016","unstructured":"Doherty DG. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun. 2016;66:60\u201375.","journal-title":"J Autoimmun"},{"key":"9622_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jaut.2018.10.020","volume":"95","author":"A Floreani","year":"2018","unstructured":"Floreani A, Restrepo-Jim\u00e9nez P, Secchi MF, et al. \u201cEtiopathogenesis of autoimmune hepatitis,\u201d (in eng). J Autoimmun. 2018;95:133\u201343.","journal-title":"J Autoimmun"},{"issue":"1","key":"9622_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000282067","volume":"28","author":"M Hardtke-Wolenski","year":"2010","unstructured":"Hardtke-Wolenski M, Jaeckel E. \u201cMouse models for experimental autoimmune hepatitis: limits and chances,\u201d (in eng). Digestive diseases (Basel, Switzerland). 2010;28(1):70\u20139.","journal-title":"Digestive diseases (Basel, Switzerland)"},{"issue":"5","key":"9622_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","volume":"101","author":"S Sakaguchi","year":"2000","unstructured":"Sakaguchi S. \u201cRegulatory T cells: key controllers of immunologic self-tolerance,\u201d (in eng). Cell. 2000;101(5):455\u20138.","journal-title":"Cell"},{"issue":"2","key":"9622_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2010.10.005","volume":"54","author":"IN Crispe","year":"2011","unstructured":"Crispe IN. \u201cLiver antigen-presenting cells,\u201d (in eng). J Hepatol. 2011;54(2):357\u201365.","journal-title":"J Hepatol"},{"issue":"4","key":"9622_CR29","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/hep.24508","volume":"54","author":"MR Ebrahimkhani","year":"2011","unstructured":"Ebrahimkhani MR, Mohar I, Crispe IN. \u201cCross-presentation of antigen by diverse subsets of murine liver cells,\u201d (in eng). Hepatology (Baltimore, MD). 2011;54(4):1379\u201387.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaut.2012.11.001","volume":"42","author":"J Ehser","year":"2013","unstructured":"Ehser J, Holdener M, Christen S, et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun. 2013;42:39\u201349.","journal-title":"J Autoimmun"},{"issue":"6","key":"9622_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bpg.2011.09.009","volume":"25","author":"R Liberal","year":"2011","unstructured":"Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. \u201cPathogenesis of autoimmune hepatitis,\u201d (in eng). Best Pract Res Clin Gastroenterol. 2011;25(6):653\u201364.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"9622_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.autrev.2005.01.005","volume":"4","author":"Y Ichiki","year":"2005","unstructured":"Ichiki Y, Aoki CA, Bowlus CL, Shimoda S, Ishibashi H, Gershwin ME. \u201cT cell immunity in autoimmune hepatitis,\u201d (in eng). Autoimmun Rev. 2005;4(5):315\u201321.","journal-title":"Autoimmun Rev"},{"key":"9622_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.814155","volume":"12","author":"R Fasano","year":"2021","unstructured":"Fasano R, Malerba E, Prete M, et al. \u201cImpact of antigen presentation mechanisms on immune response in autoimmune hepatitis,\u201d (in eng). Front Immunol. 2021;12:814155.","journal-title":"Front Immunol"},{"key":"9622_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746436","volume":"12","author":"M Vuerich","year":"2021","unstructured":"Vuerich M, Wang N, Kalbasi A, Graham JJ, Longhi MS. \u201cDysfunctional immune regulation in autoimmune hepatitis: from pathogenesis to novel therapies,\u201d (in eng). Front Immunol. 2021;12:746436.","journal-title":"Front Immunol"},{"issue":"2","key":"9622_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","volume":"75","author":"K Schroder","year":"2004","unstructured":"Schroder K, Hertzog PJ, Ravasi T, Hume DA. \u201cInterferon-gamma: an overview of signals, mechanisms and functions,\u201d (in eng). J Leukoc Biol. 2004;75(2):163\u201389.","journal-title":"J Leukoc Biol"},{"key":"9622_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.005","volume":"75","author":"R Liberal","year":"2016","unstructured":"Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. \u201cCutting edge issues in autoimmune hepatitis,\u201d (in eng). J Autoimmun. 2016;75:6\u201319.","journal-title":"J Autoimmun"},{"key":"9622_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102376","volume":"110","author":"C Scheinecker","year":"2020","unstructured":"Scheinecker C, G\u00f6schl L, Bonelli M. \u201cTreg cells in health and autoimmune diseases: new insights from single cell analysis,\u201d (in eng). J Autoimmun. 2020;110: 102376.","journal-title":"J Autoimmun"},{"issue":"2","key":"9622_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MOG.0000000000000701","volume":"37","author":"C Weiler-Normann","year":"2021","unstructured":"Weiler-Normann C, Lohse AW. \u201cAutoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation,\u201d (in eng). Curr Opin Gastroenterol. 2021;37(2):86\u201390.","journal-title":"Curr Opin Gastroenterol"},{"key":"9622_CR39","doi-asserted-by":"crossref","unstructured":"L Zhao, Y Tang, Z You, et al. \"Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression,\" (in eng). PloS One. 2011;6(4):e18909.","DOI":"10.1371\/journal.pone.0018909"},{"issue":"1","key":"9622_CR40","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hep.27087","volume":"60","author":"A Ikeda","year":"2014","unstructured":"Ikeda A, Aoki N, Kido M, et al. \u201cProgression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice,\u201d (in eng). Hepatology (Baltimore, MD). 2014;60(1):224\u201336.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1046\/j.1365-2249.2001.01391.x","volume":"123","author":"K Nishioji","year":"2001","unstructured":"Nishioji K, Okanoue T, Itoh Y, et al. \u201cIncrease of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes,\u201d (in eng). Clin Exp Immunol. 2001;123(2):271\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9622_CR42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2002-04-1164","volume":"101","author":"Y Delneste","year":"2003","unstructured":"Delneste Y, Charbonnier P, Herbault N, et al. \u201cInterferon-gamma switches monocyte differentiation from dendritic cells to macrophages,\u201d (in eng). Blood. 2003;101(1):143\u201350.","journal-title":"Blood"},{"issue":"2","key":"9622_CR43","first-page":"223","volume":"14","author":"F Autschbach","year":"1991","unstructured":"Autschbach F, Meuer SC, Moebius U, et al. Hepatocellular expression of lymphocyte function\u2014associated antigen 3 in chronic hepatitis. Hepatology (Baltimore, MD). 1991;14(2):223\u201330.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"9622_CR44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.gastro.2005.12.020","volume":"130","author":"Y Ma","year":"2006","unstructured":"Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130(3):868\u201382.","journal-title":"Gastroenterology"},{"issue":"2","key":"9622_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/hep.21658","volume":"46","author":"MS Longhi","year":"2007","unstructured":"Longhi MS, Hussain MJ, Bogdanos DP, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology (Baltimore, MD). 2007;46(2):472\u201384.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"9622_CR46","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jhep.2020.05.053","volume":"73","author":"A Renand","year":"2020","unstructured":"Renand A, Cervera-Marzal I, Gil L, et al. \u201cIntegrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis,\u201d (in eng). J Hepatol. 2020;73(6):1379\u201390.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR47","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.31739","volume":"74","author":"Z You","year":"2021","unstructured":"You Z, Li Y, Wang Q, et al. \u201cThe clinical significance of hepatic CD69(+) CD103(+) CD8(+) resident-memory T cells in autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2021;74(2):847\u201363.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"9622_CR48","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/hep.27991","volume":"62","author":"K B\u00e9land","year":"2015","unstructured":"B\u00e9land K, Marceau G, Labardy A, Bourbonnais S, Alvarez F. \u201cDepletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells,\u201d (in eng). Hepatology (Baltimore, MD). Nov2015;62(5):1511\u201323.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR49","first-page":"7181685","volume":"2016","author":"NN Than","year":"2016","unstructured":"Than NN, Jeffery HC, Oo YH. \u201cAutoimmune hepatitis: progress from global immunosuppression to personalised regulatory T cell therapy,\u201d (in eng). Can J Gastroenterol Hepatol. 2016;2016:7181685.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"9622_CR50","doi-asserted-by":"crossref","unstructured":"MS Longhi, MJ Hussain, RR Mitry, et al. \"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis,\" (in eng). J Immunol (Baltimore, Md : 1950). 2006;176(7):4484\u201391.","DOI":"10.4049\/jimmunol.176.7.4484"},{"issue":"3","key":"9622_CR51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/hep.27884","volume":"62","author":"R Liberal","year":"2015","unstructured":"Liberal R, Grant CR, Holder BS, et al. \u201cIn autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression,\u201d (in eng). Hepatology (Baltimore, MD). 2015;62(3):863\u201375.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR52","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/hep.24039","volume":"53","author":"MS Longhi","year":"2011","unstructured":"Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. \u201cAutoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2011;53(2):536\u201347.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"9622_CR53","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.23792","volume":"52","author":"S Ferri","year":"2010","unstructured":"Ferri S, Longhi MS, De Molo C, et al. \u201cA multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2010;52(3):999\u20131007.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2005.05.001","volume":"25","author":"MS Longhi","year":"2005","unstructured":"Longhi MS, Ma Y, Mitry RR, et al. \u201cEffect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis,\u201d (in eng). J Autoimmun. 2005;25(1):63\u201371.","journal-title":"J Autoimmun"},{"key":"9622_CR55","unstructured":"BE Behairy, HA El-Araby, HH Abd El Kader, et al. \" Assessment of intrahepatic regulatory T cells in children with autoimmune hepatitis,\" (in eng). Ann Hepatol. 2016;15(5):682\u201390."},{"issue":"5","key":"9622_CR56","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2014.05.034","volume":"61","author":"R Taubert","year":"2014","unstructured":"Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol. 2014;61(5):1106\u201314.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR57","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/hep.24080","volume":"53","author":"RT Stravitz","year":"2011","unstructured":"Stravitz RT, Lefkowitch JH, Fontana RJ, et al. \u201cAutoimmune acute liver failure: proposed clinical and histological criteria,\u201d (in eng). Hepatology (Baltimore, MD). 2011;53(2):517\u201326.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/hep.20732","volume":"42","author":"JJ Feld","year":"2005","unstructured":"Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. \u201cAutoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome,\u201d (in eng). Hepatology (Baltimore, MD). 2005;42(1):53\u201362.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","volume":"35","author":"J Kogan","year":"2002","unstructured":"Kogan J, Safadi R, Ashur Y, Shouval D, Ilan Y. \u201cPrognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients,\u201d (in eng). J Clin Gastroenterol. 2002;35(1):75\u201381.","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"9622_CR60","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/j.1365-2036.2006.02894.x","volume":"23","author":"Y Miyake","year":"2006","unstructured":"Miyake Y, Iwasaki Y, Terada R, et al. \u201cClinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases,\u201d (in eng). Aliment Pharmacol Ther. 2006;23(9):1347\u201353.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"9622_CR61","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1542-3565(04)00246-0","volume":"2","author":"WR Kessler","year":"2004","unstructured":"Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. \u201cFulminant hepatic failure as the initial presentation of acute autoimmune hepatitis,\u201d (in eng). Clin Gastroenterol Hepatol : Offi Clin Prac J Am Gastroenterol Asso. 2004;2(7):625\u201331.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"10","key":"9622_CR62","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","volume":"49","author":"NM van Gerven","year":"2014","unstructured":"van Gerven NM, Verwer BJ, Witte BI, et al. \u201cEpidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands,\u201d (in eng). Scand J Gastroenterol. 2014;49(10):1245\u201354.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"9622_CR63","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/apt.12470","volume":"38","author":"K Zachou","year":"2013","unstructured":"Zachou K, Muratori P, Koukoulis GK, et al. \u201cReview article: autoimmune hepatitis \u2013 current management and challenges,\u201d (in eng). Aliment Pharmacol Ther. 2013;38(8):887\u2013913.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9622_CR64","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja AJ, et al. \u201cSimplified criteria for the diagnosis of autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2008;48(1):169\u201376.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"9622_CR65","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jhep.2009.01.020","volume":"50","author":"P Muratori","year":"2009","unstructured":"Muratori P, Granito A, Quarneti C, et al. \u201cAutoimmune hepatitis in Italy: the Bologna experience,\u201d (in eng). J Hepatol. 2009;50(6):1210\u20138.","journal-title":"J Hepatol"},{"issue":"3","key":"9622_CR66","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","volume":"55","author":"K Zachou","year":"2011","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. \u201cMycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients,\u201d (in eng). J Hepatol. 2011;55(3):636\u201346.","journal-title":"J Hepatol"},{"issue":"12","key":"9622_CR67","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1136\/gut.2010.235259","volume":"60","author":"D Gleeson","year":"2011","unstructured":"Gleeson D, Heneghan MA. \u201cBritish Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis,\u201d (in eng). Gut. 2011;60(12):1611\u201329.","journal-title":"Gut"},{"key":"9622_CR68","doi-asserted-by":"crossref","unstructured":"Liberal R, Grant CR, Longhi MS, Mieli-Vergani G and Vergani D. \"Diagnostic criteria of autoimmune hepatitis,\" (in eng). Autoimmun Rev. 2014;13(4\u20135):435\u201340.","DOI":"10.1016\/j.autrev.2013.11.009"},{"issue":"4","key":"9622_CR69","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jhep.2006.04.007","volume":"45","author":"T Al-Chalabi","year":"2006","unstructured":"Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. \u201cAutoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre,\u201d (in eng). J Hepatol. 2006;45(4):575\u201383.","journal-title":"J Hepatol"},{"issue":"4","key":"9622_CR70","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/hep.1840180435","volume":"18","author":"PJ Johnson","year":"1993","unstructured":"Johnson PJ, McFarlane IG. \u201cMeeting report: International Autoimmune Hepatitis Group,\u201d (in eng). Hepatology (Baltimore, MD). 1993;18(4):998\u20131005.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"9622_CR71","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5009\/gnl19261","volume":"14","author":"A Tanaka","year":"2020","unstructured":"Tanaka A. \u201cAutoimmune Hepatitis: 2019 Update,\u201d (in eng). Gut Liver. 2020;14(4):430\u20138.","journal-title":"Gut and liver"},{"issue":"5","key":"9622_CR72","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"AW Lohse","year":"2022","unstructured":"Lohse AW, Sebode M, Bhathal PS, et al. Consensus recommendations for histological criteria of autoimmune hepatitis from the international AIH pathology group: results of a workshop on AIH histology hosted by the european reference network on hepatological diseases and the european society of pathology: results of a workshop on AIH histology hosted by the european reference network on hepatological diseases and the european society of pathology liver international. 2022;42(5):1058\u201369.","journal-title":"Liver Int"},{"issue":"3","key":"9622_CR73","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s00535-010-0316-3","volume":"46","author":"S Yasui","year":"2011","unstructured":"Yasui S, Fujiwara K, Yonemitsu Y, Oda S, Nakano M, Yokosuka O. \u201cClinicopathological features of severe and fulminant forms of autoimmune hepatitis,\u201d (in eng). J Gastroenterol. 2011;46(3):378\u201390.","journal-title":"J Gastroenterol"},{"key":"9622_CR74","doi-asserted-by":"crossref","unstructured":"Ben Ari Z, Mehta A, Lennard\u00a0 L and Burroughs AK. \"Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis,\" (in eng). J Hepatol 1995;23(3):351\u20134.","DOI":"10.1016\/0168-8278(95)80481-1"},{"issue":"9","key":"9622_CR75","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/apt.13796","volume":"44","author":"X Zhu","year":"2016","unstructured":"Zhu X, Wang XD, Chao K, et al. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in chinese patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2016;44(9):967\u201375.","journal-title":"Aliment Pharmacol Ther"},{"key":"9622_CR76","doi-asserted-by":"crossref","unstructured":"Fan X, Yin D, Men R, Xu H, Yang L. NUDT15 polymorphism confer increased susceptibility to thiopurine-induced leukopenia in patients with autoimmune hepatitis and related cirrhosis. Front Pharmacol. 2019;10:346. Published 2019 Apr 9.","DOI":"10.3389\/fphar.2019.00346"},{"issue":"4","key":"9622_CR77","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/jhep.2002.32485","volume":"35","author":"AJ Czaja","year":"2002","unstructured":"Czaja AJ, Menon KV, Carpenter HA. \u201cSustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis,\u201d (in eng). Hepatology (Baltimore, MD). 2002;35(4):890\u20137.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR78","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/jhep.2002.30991","volume":"35","author":"MA Heneghan","year":"2002","unstructured":"Heneghan MA, McFarlane IG. \u201cCurrent and novel immunosuppressive therapy for autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2002;35(1):7\u201313.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"7","key":"9622_CR79","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/ajg.2015.139","volume":"110","author":"HK Dhaliwal","year":"2015","unstructured":"Dhaliwal HK, Hoeroldt BS, Dube AK, et al. \u201cLong-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis,\u201d (in eng). Am J Gastroenterol. 2015;110(7):993\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9622_CR80","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jhep.2017.11.020","volume":"68","author":"J Hartl","year":"2018","unstructured":"Hartl J, Ehlken H, Sebode M, et al. \u201cUsefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis,\u201d (in eng). J Hepatol. 2018;68(4):754\u201363.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MEG.0000000000001019","volume":"30","author":"M De Lemos-Bonotto","year":"2018","unstructured":"De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, Mattos AA, Azeredo-da-Silva ALF. \u201cA systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment,\u201d (in eng). Eur J Gastroenterol Hepatol. 2018;30(2):212\u20136.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"9622_CR82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2009.02.024","volume":"51","author":"MM Aw","year":"2009","unstructured":"Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. \u201cMycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up,\u201d (in eng). J Hepatol. 2009;51(1):156\u201360.","journal-title":"J Hepatol"},{"issue":"4","key":"9622_CR83","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1586\/egh.11.45","volume":"5","author":"HI Fallatah","year":"2011","unstructured":"Fallatah HI, Akbar HO. \u201cMycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy,\u201d (in eng). Expert Rev Gastroenterol Hepatol. 2011;5(4):517\u201322.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"9622_CR84","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MPG.0000000000001530","volume":"65","author":"AN Zizzo","year":"2017","unstructured":"Zizzo AN, Valentino PL, Shah PS, Kamath BM. \u201cSecond-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis,\u201d (in eng). J Pediatr Gastroenterol Nutr. 2017;65(1):6\u201315.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"9622_CR85","doi-asserted-by":"crossref","unstructured":"B Terziroli Beretta-Piccoli, G Mieli-Vergani and D Vergani. \"Autoimmune hepatitis: standard treatment and systematic review of alternative treatments,\" (in eng). World J Gastroenterol. 2017;23(33):6030\u201348.","DOI":"10.3748\/wjg.v23.i33.6030"},{"issue":"3","key":"9622_CR86","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/hep.24141","volume":"53","author":"AD Yeoman","year":"2011","unstructured":"Yeoman AD, Westbrook RH, Zen Y, et al. \u201cEarly predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2011;53(3):926\u201334.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"9622_CR87","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","volume":"34","author":"MM Tannous","year":"2011","unstructured":"Tannous MM, Cheng J, Muniyappa K, et al. \u201cUse of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience,\u201d (in eng). Aliment Pharmacol Ther. 2011;34(3):405\u20137.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"9622_CR88","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","volume":"15","author":"C Efe","year":"2017","unstructured":"Efe C, Hagstr\u00f6m H, Ytting H, et al. \u201cEfficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis,\u201d (in eng). Clin Gastroenterol Hepatol : Offi Clin Prac J Am Gastroenterol Asso. 2017;15(12):1950-6.e1.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"5","key":"9622_CR89","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1007\/s10620-018-5011-x","volume":"63","author":"C Efe","year":"2018","unstructured":"Efe C, Taii HA, Ytting H, et al. \u201cTacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis,\u201d (in eng). Dig Dis Sci. 2018;63(5):1348\u201354.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"9622_CR90","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3109\/00365521.2015.1095351","volume":"51","author":"NN Than","year":"2016","unstructured":"Than NN, Wiegard C, Weiler-Normann C, et al. \u201cLong-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy,\u201d (in eng). Scand J Gastroenterol. 2016;51(3):329\u201336.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"9622_CR91","first-page":"571","volume":"35","author":"S Kanzler","year":"1997","unstructured":"Kanzler S, Gerken G, Dienes HP. KH Meyer zum B\u00fcschenfelde and AW Lohse, \u201cCyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2013report of three cases,\u201d (in eng). Z Gastroenterol. l1997;35(7):571\u20138.","journal-title":"Z Gastroenterol"},{"issue":"6","key":"9622_CR92","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0168-8278(98)80128-1","volume":"29","author":"KW Burak","year":"1998","unstructured":"Burak KW, Urbanski SJ, Swain MG. \u201cSuccessful treatment of refractory type 1 autoimmune hepatitis with methotrexate,\u201d (in eng). J Hepatol. 1998;29(6):990\u20133.","journal-title":"J Hepatol"},{"key":"9622_CR93","doi-asserted-by":"crossref","unstructured":"Burak KW, Swain MG, Santodomingo-Garzon T, et al. \"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy,\" (in eng). Canadian J Gastroenterol = J Canadien de Gastroenterol. 2013;27(5):273\u201380.","DOI":"10.1155\/2013\/512624"},{"issue":"3","key":"9622_CR94","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","volume":"58","author":"C Weiler-Normann","year":"2013","unstructured":"Weiler-Normann C, Schramm C, Quaas A, et al. \u201cInfliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis,\u201d (in eng). J Hepatol. 2013;58(3):529\u201334.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR95","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000336704","volume":"30","author":"J Lata","year":"2012","unstructured":"Lata J. \u201cDiagnosis and treatment of autoimmune hepatitis,\u201d (in eng). Dig Dis (Basel, Switzerland). 2012;30(2):212\u20135.","journal-title":"Digestive diseases (Basel, Switzerland)"},{"issue":"2","key":"9622_CR96","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","volume":"72","author":"CL Mack","year":"2020","unstructured":"Mack CL, Adams D, Assis DN, et al. \u201cDiagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the american association for the study of liver diseases,\u201d (in eng). Hepatology (Baltimore, MD). 2020;72(2):671\u2013722.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"10","key":"9622_CR97","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/apt.13584","volume":"43","author":"K Zachou","year":"2016","unstructured":"Zachou K, Gatselis NK, Arvaniti P, et al. \u201cA real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis,\u201d (in eng). Aliment Pharmacol Ther. 2016;43(10):1035\u201347.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"9622_CR98","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","volume":"43","author":"M Cuarterolo","year":"2006","unstructured":"Cuarterolo M, Ciocca M, Velasco CC, et al. \u201cFollow-up of children with autoimmune hepatitis treated with cyclosporine,\u201d (in eng). J Pediatr Gastroenterol Nutr. 2006;43(5):635\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"9622_CR99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-065X.2012.01152.x","volume":"249","author":"AT Waickman","year":"2012","unstructured":"Waickman AT, Powell JD. \u201cmTOR, metabolism, and the regulation of T-cell differentiation and function,\u201d (in eng). Immunol Rev. 2012;249(1):43\u201358.","journal-title":"Immunol Rev"},{"issue":"2","key":"9622_CR100","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","volume":"66","author":"G Mieli-Vergani","year":"2018","unstructured":"Mieli-Vergani G, Vergani D, Baumann U, et al. \u201cDiagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement,\u201d (in eng). J Pediatr Gastroenterol Nutr. 2018;66(2):345\u201360.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"9622_CR101","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1097\/MEG.0000000000001367","volume":"31","author":"ZJ Yu","year":"2019","unstructured":"Yu ZJ, Zhang LL, Huang TT, Zhu JS, He ZB. \u201cComparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis,\u201d (in eng). Eur J Gastroenterol Hepatol. 2019;31(7):873\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"9622_CR102","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1440-1746.2012.07292.x","volume":"28","author":"BH Kim","year":"2013","unstructured":"Kim BH, Kim YJ, Jeong SH, et al. \u201cClinical features of autoimmune hepatitis and comparison of two diagnostic criteria in Korea: a nationwide, multicenter study,\u201d (in eng). J Gastroenterol Hepatol. 2013;28(1):128\u201334.","journal-title":"J Gastroenterol Hepatol"},{"key":"9622_CR103","doi-asserted-by":"crossref","unstructured":"A Tanaka, X Ma, O Yokosuka, et al. \"Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016,\" (in eng). Hepatol Int. 2016;10(6):909\u201315.","DOI":"10.1007\/s12072-016-9767-9"},{"issue":"9","key":"9622_CR104","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/liv.13724","volume":"38","author":"V Gordon","year":"2018","unstructured":"Gordon V, Adhikary R, Appleby V, et al. \u201cDiagnosis, presentation and initial severity of autoimmune hepatitis (AIH) in patients attending 28 hospitals in the UK,\u201d (in eng). Liver Int. 2018;38(9):1686\u201395.","journal-title":"Liver Int"},{"issue":"1","key":"9622_CR105","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/liv.13960","volume":"39","author":"MK Janik","year":"2019","unstructured":"Janik MK, Wunsch E, Raszeja-Wyszomirska J, et al. \u201cAutoimmune hepatitis exerts a profound, negative effect on health-related quality of life: a prospective, single-centre study,\u201d (in eng). Liver Int. 2019;39(1):215\u201321.","journal-title":"Liver Int"},{"issue":"2","key":"9622_CR106","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/MOG.0000000000000704","volume":"37","author":"A Cardon","year":"2021","unstructured":"Cardon A, Conchon S, Renand A. \u201cMechanisms of autoimmune hepatitis,\u201d (in eng). Curr Opin Gastroenterol. 2021;37(2):79\u201385.","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"9622_CR107","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","volume":"1","author":"YH Oo","year":"2019","unstructured":"Oo YH, Ackrill S, Cole R, et al. \u201cLiver homing of clinical grade tregs after therapeutic infusion in patients with autoimmune hepatitis,\u201d (in eng). JHEP Rep\u202f: Innov Hepatol. 2019;1(4):286\u201396.","journal-title":"JHEP reports : innovation in hepatology"},{"key":"9622_CR108","doi-asserted-by":"crossref","unstructured":"Diestelhorst J, Junge N, Jonigk D, et al. \"Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis,\" (in eng). Sci Rep. 2018;8(1):419.","DOI":"10.1038\/s41598-017-18818-5"},{"issue":"3","key":"9622_CR109","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.12940","volume":"188","author":"HC Jeffery","year":"2017","unstructured":"Jeffery HC, Jeffery LE, Lutz P, et al. \u201cLow-dose interleukin-2 promotes STAT-5 phosphorylation, T(reg) survival and CTLA-4-dependent function in autoimmune liver diseases,\u201d (in eng). Clin Exp Immunol. 2017;188(3):394\u2013411.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"9622_CR110","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/hep.30059","volume":"68","author":"TY Lim","year":"2018","unstructured":"Lim TY, Martinez-Llordella M, Kodela E, Gray E, Heneghan MA, Sanchez-Fueyo A. \u201cLow-dose interleukin-2 for refractory autoimmune hepatitis,\u201d (in eng). Hepatology (Baltimore, MD). 2018;68(4):1649\u201352.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"11","key":"9622_CR111","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","volume":"127","author":"H Chatrath","year":"2014","unstructured":"Chatrath H, Allen L, Boyer TD. \u201cUse of sirolimus in the treatment of refractory autoimmune hepatitis,\u201d (in eng). Am J Med. 2014;127(11):1128\u201331.","journal-title":"Am J Med"},{"issue":"1","key":"9622_CR112","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1097\/MPG.0b013e318291feaa","volume":"58","author":"J Kurowski","year":"2014","unstructured":"Kurowski J, Melin-Aldana H, Bass L, Alonso EM, Ekong UD. \u201cSirolimus as rescue therapy in pediatric autoimmune hepatitis,\u201d (in eng). J Pediatr Gastroenterol Nutr. 2014;58(1):e4-6.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"9622_CR113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2020.06.044","volume":"74","author":"M Vuerich","year":"2021","unstructured":"Vuerich M, Harshe R, Frank LA, et al. \u201cAltered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis,\u201d (in eng). J Hepatol. 2021;74(1):48\u201357.","journal-title":"J Hepatol"},{"issue":"3","key":"9622_CR114","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1159\/000322693","volume":"4","author":"E Barth","year":"2010","unstructured":"Barth E, Clawson J. \u201cA case of autoimmune hepatitis treated with rituximab,\u201d (in eng). Case Rep Gastroenterol. 2010;4(3):502\u20139.","journal-title":"Case Rep Gastroenterol"},{"issue":"12","key":"9622_CR115","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003194","volume":"95","author":"H Nishikawa","year":"2016","unstructured":"Nishikawa H, Enomoto H, Iwata Y, et al. \u201cB-cell activating factor belonging to the tumor necrosis factor family and interferon-\u03b3-inducible protein-10 in autoimmune hepatitis,\u201d (in eng). Medicine. 2016;95(12): e3194.","journal-title":"Medicine"},{"key":"9622_CR116","unstructured":"Johnsson HJ and McInnes IB. \"Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis,\" (in eng). Clin Exp Rheumatol. 2015;33(5 Suppl 93):S115\u20138."},{"issue":"4","key":"9622_CR117","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clinthera.2012.02.014","volume":"34","author":"I Navarro-Mill\u00e1n","year":"2012","unstructured":"Navarro-Mill\u00e1n I, Singh JA, Curtis JR. \u201cSystematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor,\u201d (in eng). Clin Ther. 2012;34(4):788-802.e3.","journal-title":"Clin Ther"},{"issue":"6","key":"9622_CR118","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.bpg.2017.09.013","volume":"31","author":"W Cai","year":"2017","unstructured":"Cai W, Ran Y, Li Y, Wang B, Zhou L. \u201cIntestinal microbiome and permeability in patients with autoimmune hepatitis,\u201d (in eng). Best Pract Res Clin Gastroenterol. 2017;31(6):669\u201373.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"9622_CR119","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2018-317836","volume":"69","author":"Y Wei","year":"2020","unstructured":"Wei Y, Li Y, Yan L, et al. \u201cAlterations of gut microbiome in autoimmune hepatitis,\u201d (in eng). Gut. 2020;69(3):569\u201377.","journal-title":"Gut"},{"key":"9622_CR120","doi-asserted-by":"crossref","unstructured":"Lotfy A, Elgamal A, Burdzinska A, et al. \"Stem cell therapies for autoimmune hepatitis,\" (in eng). Stem Cell Res Ther. 2021;12(1):386.","DOI":"10.1186\/s13287-021-02464-w"},{"issue":"10","key":"9622_CR121","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/cas.13334","volume":"108","author":"HY Lee","year":"2017","unstructured":"Lee HY, Hong IS. \u201cDouble-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential,\u201d (in eng). Cancer Sci. 2017;108(10):1939\u201346.","journal-title":"Cancer Sci"},{"issue":"6","key":"9622_CR122","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/bmt.2011.185","volume":"47","author":"JA Snowden","year":"2012","unstructured":"Snowden JA, Saccardi R, Allez M, et al. \u201cHaematopoietic SCT in severe autoimmune diseases: updated guidelines of the european group for blood and marrow transplantation,\u201d (in eng). Bone Marrow Transplant. 2012;47(6):770\u201390.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"9622_CR123","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.cgh.2015.08.025","volume":"13","author":"U Beuers","year":"2015","unstructured":"Beuers U, Gershwin ME, Gish RG, et al. \u201cChanging nomenclature for PBC: from \u2018cirrhosis\u2019 to \u2018cholangitis\u2019,\u201d (in eng). Clin Gastroenterol Hepatol : Official Clinical Prac J Am Gastroenterol Asso. 2015;13(11):1867\u20139.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"key":"9622_CR124","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis, (in eng). J Hepatol. 2017;67(1):145\u201372.","DOI":"10.1016\/j.jhep.2017.03.022"},{"issue":"4","key":"9622_CR125","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. \u201cSurvival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years,\u201d (in eng). Gastroenterology. 2002;123(4):1044\u201351.","journal-title":"Gastroenterology"},{"issue":"5","key":"9622_CR126","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.20907","volume":"42","author":"ME Gershwin","year":"2005","unstructured":"Gershwin ME, Selmi C, Worman HJ, et al. \u201cRisk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients,\u201d (in eng). Hepatology (Baltimore, MD). 2005;42(5):1194\u2013202.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"9","key":"9622_CR127","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/liv.13143","volume":"36","author":"AF Gulamhusein","year":"2016","unstructured":"Gulamhusein AF, Juran BD, Atkinson EJ, McCauley B, Schlicht E, Lazaridis KN. \u201cLow incidence of primary biliary cirrhosis (PBC) in the first-degree relatives of PBC probands after 8 years of follow-up,\u201d (in eng). Liver Int. 2016;36(9):1378\u201382.","journal-title":"Liver Int"},{"key":"9622_CR128","doi-asserted-by":"crossref","unstructured":"Gershwin ME, Mackay IR, Sturgess A and Coppel RL. \"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis,\" (in eng). J Immunol (Baltimore, Md : 1950). 1987;138(10):3525\u201331.","DOI":"10.4049\/jimmunol.138.10.3525"},{"key":"9622_CR129","doi-asserted-by":"crossref","unstructured":"\"EASL Clinical Practice Guidelines: management of cholestatic liver diseases,\" (in eng). J Hepatol. 2009;51(2):237\u201367.","DOI":"10.1016\/j.jhep.2009.04.009"},{"issue":"2","key":"9622_CR130","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1055\/s-2007-979469","volume":"27","author":"P Invernizzi","year":"2007","unstructured":"Invernizzi P, Lleo A, Podda M. \u201cInterpreting serological tests in diagnosing autoimmune liver diseases,\u201d (in eng). Semin Liver Dis. 2007;27(2):161\u201372.","journal-title":"Semin Liver Dis"},{"key":"9622_CR131","doi-asserted-by":"crossref","unstructured":"Hirschfield GM and Heathcote EJ. \"Antimitochondrial antibody-negative primary biliary cirrhosis,\" (in eng). Clin Liver Dis. 2008;12(2):323\u201331; viii-ix.","DOI":"10.1016\/j.cld.2008.02.003"},{"issue":"4","key":"9622_CR132","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","volume":"41","author":"D Vergani","year":"2004","unstructured":"Vergani D, Alvarez F, Bianchi FB, et al. \u201cLiver autoimmune serology: a consensus statement from the committee for autoimmune serology of the international autoimmune hepatitis group,\u201d (in eng). J Hepatol. 2004;41(4):677\u201383.","journal-title":"J Hepatol"},{"issue":"6","key":"9622_CR133","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/hep.22567","volume":"48","author":"P Invernizzi","year":"2008","unstructured":"Invernizzi P, Selmi C, Poli F, et al. \u201cHuman leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls,\u201d (in eng). Hepatology (Baltimore, MD). 2008;48(6):1906\u201312.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"9622_CR134","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/hep.21316","volume":"44","author":"PT Donaldson","year":"2006","unstructured":"Donaldson PT, Baragiotta A, Heneghan MA, et al. \u201cHLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study,\u201d (in eng). Hepatology (Baltimore, MD). 2006;44(3):667\u201374.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"9622_CR135","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/ng.789","volume":"43","author":"GF Mells","year":"2011","unstructured":"Mells GF, Floyd JA, Morley KI, et al. \u201cGenome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis,\u201d (in eng). Nat Genet. 2011;43(4):329\u201332.","journal-title":"Nat Genet"},{"issue":"9408","key":"9622_CR136","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(04)15541-4","volume":"363","author":"P Invernizzi","year":"2004","unstructured":"Invernizzi P, Miozzo M, Battezzati PM, et al. \u201cFrequency of monosomy x in women with primary biliary cirrhosis,\u201d (in eng). Lancet (London, England). 2004;363(9408):533\u20135.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"9622_CR137","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwt308","volume":"179","author":"RJ McNally","year":"2014","unstructured":"McNally RJ, James PW, Ducker S, Norman PD, James OF. \u201cNo rise in incidence but geographical heterogeneity in the occurrence of primary biliary cirrhosis in North East England,\u201d (in eng). Am J Epidemiol. 2014;179(4):492\u20138.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"9622_CR138","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/hep.21076","volume":"43","author":"A Ala","year":"2006","unstructured":"Ala A, Stanca CM, Bu-Ghanim M, et al. \u201cIncreased prevalence of primary biliary cirrhosis near Superfund toxic waste sites,\u201d (in eng). Hepatology (Baltimore, MD). 2006;43(3):525\u201331.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR139","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00535-021-01836-6","volume":"57","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto K, Ohfuji S, Abe M, et al. Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study. J Gastroenterol. 2022;57(1):19\u201329.","journal-title":"J Gastroenterol"},{"key":"9622_CR140","doi-asserted-by":"publisher","first-page":"197","DOI":"10.15403\/jgld-181","volume":"28","author":"K Wijarnpreecha","year":"2019","unstructured":"Wijarnpreecha K, Werlang M, Panjawatanan P, et al. \u201cAssociation between smoking and risk of primary biliary cholangitis: a systematic review and meta-analysis,\u201d (in eng). J Gastrointestin Liver Dis : JGLD. 2019;28:197\u2013203.","journal-title":"Journal of gastrointestinal and liver diseases : JGLD"},{"key":"9622_CR141","doi-asserted-by":"crossref","unstructured":"Triger DR. \"Primary biliary cirrhosis: is there an environmental contribution?,\" (in eng). J Gastroenterol Hepatol. 1991;6(6):568\u20139.","DOI":"10.1111\/j.1440-1746.1991.tb00911.x"},{"issue":"5","key":"9622_CR142","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0168-8278(94)80255-6","volume":"21","author":"J O'Donohue","year":"1994","unstructured":"O\u2019Donohue J, McFarlane B, Bomford A, Yates M, Williams R. \u201cAntibodies to atypical mycobacteria in primary biliary cirrhosis,\u201d (in eng). J Hepatol. 1994;21(5):887\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"9622_CR143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1053\/jhep.2001.21165","volume":"33","author":"A Parikh-Patel","year":"2001","unstructured":"Parikh-Patel A, Gold EB, Worman H, Krivy KE, Gershwin ME. \u201cRisk factors for primary biliary cirrhosis in a cohort of patients from the united states,\u201d (in eng). Hepatology (Baltimore, MD). 2001;33(1):16\u201321.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR144","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hep.32172","volume":"75","author":"Y Yang","year":"2022","unstructured":"Yang Y, Choi J, Chen Y, et al. E. coli and the etiology of human PBC: antimitochondrial antibodies and spreading determinants. Hepatology (Baltimore, MD). 2022;75(2):266\u201379.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111754","volume":"140","author":"H Li","year":"2021","unstructured":"Li H, Guan Y, Han C, et al. \u201cThe pathogenesis, models and therapeutic advances of primary biliary cholangitis,\u201d (in eng). Biomed Pharmacother. 2021;140: 111754.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"9622_CR146","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","volume":"16","author":"Y Li","year":"2017","unstructured":"Li Y, Tang R, Leung PSC, Gershwin ME, Ma X. \u201cBile acids and intestinal microbiota in autoimmune cholestatic liver diseases,\u201d (in eng). Autoimmun Rev. 2017;16(9):885\u201396.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"9622_CR147","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1053\/jhep.2002.33634","volume":"35","author":"S Melero","year":"2002","unstructured":"Melero S, Spirl\u00ec C, Zsembery A, et al. \u201cDefective regulation of cholangiocyte Cl-\/HCO3(-) and Na+\/H+ exchanger activities in primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2002;35(6):1513\u201321.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR148","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0016-5085(99)70564-0","volume":"117","author":"J Prieto","year":"1999","unstructured":"Prieto J, Garc\u00eda N, Mart\u00ed-Climent JM, Pe\u00f1uelas I, Richter JA, Medina JF. \u201cAssessment of biliary bicarbonate secretion in humans by positron emission tomography,\u201d (in eng). Gastroenterology. 1999;117(1):167\u201372.","journal-title":"Gastroenterology"},{"issue":"2","key":"9622_CR149","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/hep.21042","volume":"43","author":"JM Banales","year":"2006","unstructured":"Banales JM, Arenas F, Rodr\u00edguez-Ortigosa CM, et al. \u201cBicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger,\u201d (in eng). Hepatology (Baltimore, MD). 2006;43(2):266\u201375.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR150","first-page":"695","volume":"118","author":"F Arenas","year":"2008","unstructured":"Arenas F, Hervias I, Uriz M, Joplin R, Prieto J, Medina JF. \u201cCombination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells,\u201d (in eng). J Clin Investig. 2008;118(2):695\u2013709.","journal-title":"J Clin Investig"},{"issue":"6","key":"9622_CR151","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/hep.1840190613","volume":"19","author":"E Mart\u00ednez-Ans\u00f3","year":"1994","unstructured":"Mart\u00ednez-Ans\u00f3 E, Castillo JE, D\u00edez J, Medina JF, Prieto J. \u201cImmunohistochemical detection of chloride\/bicarbonate anion exchangers in human liver,\u201d (in eng). Hepatology (Baltimore, MD). 1994;19(6):1400\u20136.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR152","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/hep.25691","volume":"56","author":"JM Banales","year":"2012","unstructured":"Banales JM, S\u00e1ez E, Uriz M, et al. \u201cUp-regulation of microRNA 506 leads to decreased Cl-\/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2012;56(2):687\u201397.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"9622_CR153","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1053\/j.gastro.2007.08.020","volume":"133","author":"N Minagawa","year":"2007","unstructured":"Minagawa N, Nagata J, Shibao K, et al. \u201cCyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile,\u201d (in eng). Gastroenterology. 2007;133(5):1592\u2013602.","journal-title":"Gastroenterology"},{"issue":"4","key":"9622_CR154","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/hep.29533","volume":"67","author":"O Erice","year":"2018","unstructured":"Erice O, Munoz-Garrido P, Vaquero J, et al. \u201cMicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation,\u201d (in eng). Hepatology (Baltimore, MD). 2018;67(4):1420\u201340.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3","key":"9622_CR155","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22736","volume":"49","author":"A Lleo","year":"2009","unstructured":"Lleo A, Selmi C, Invernizzi P, et al. \u201cApotopes and the biliary specificity of primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2009;49(3):871\u20139.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR156","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1172\/JCI200110716","volume":"108","author":"JA Odin","year":"2001","unstructured":"Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A. \u201cBcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis,\u201d (in eng). J Clin Investig. 2001;108(2):223\u201332.","journal-title":"J Clin Investig"},{"issue":"24","key":"9622_CR157","doi-asserted-by":"publisher","first-page":"16625","DOI":"10.1074\/jbc.M602723200","volume":"281","author":"Y Yamamoto","year":"2006","unstructured":"Yamamoto Y, Moore R, Hess HA, et al. \u201cEstrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity,\u201d (in eng). J Biol Chem. 2006;281(24):16625\u201331.","journal-title":"J Biol Chem"},{"key":"9622_CR158","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.3389\/fimmu.2019.02815","volume":"10","author":"H Cao","year":"2019","unstructured":"Cao H, Zhu B, Qu Y, Zhang W. \u201cAbnormal expression of ER\u03b1 in cholangiocytes of patients with primary biliary cholangitis mediated intrahepatic bile duct inflammation,\u201d (in eng). Front Immunol. 2019;10:2815.","journal-title":"Front Immunol"},{"issue":"1","key":"9622_CR159","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/hep.24630","volume":"55","author":"A Lleo","year":"2012","unstructured":"Lleo A, Liao J, Invernizzi P, et al. \u201cImmunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2012;55(1):153\u201360.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR160","doi-asserted-by":"crossref","unstructured":"Poupon R, Chazouill\u00e8res O, Balkau B and Poupon RE. \"Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC group,\" (in eng). J Hepatol. 1999;30(3):408\u201312.","DOI":"10.1016\/S0168-8278(99)80098-1"},{"issue":"3","key":"9622_CR161","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1478-3231.2004.0918.x","volume":"24","author":"C Corpechot","year":"2004","unstructured":"Corpechot C, Poujol-Robert A, Wendum D, et al. \u201cBiochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis,\u201d (in eng). Liver Int. 2004;24(3):187\u201393.","journal-title":"Liver Int"},{"issue":"8","key":"9622_CR162","first-page":"841","volume":"49","author":"P Invernizzi","year":"2017","unstructured":"Invernizzi P, Floreani A, Carbone M, et al. \u201cPrimary Biliary Cholangitis: advances in management and treatment of the disease,\u201d (in eng). Dig Liver Dis\u202f: Offi J Italian Soc Gastroenterol Italian Asso Study Liver. 2017;49(8):841\u20136.","journal-title":"Liver"},{"issue":"1","key":"9622_CR163","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/hep.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells GF, Pells G, Newton JL, et al. \u201cImpact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study,\u201d (in eng). Hepatology (Baltimore, MD). 2013;58(1):273\u201383.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"10","key":"9622_CR164","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/apt.13794","volume":"44","author":"JK Dyson","year":"2016","unstructured":"Dyson JK, Wilkinson N, Jopson L, et al. \u201cThe inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis,\u201d (in eng). Aliment Pharmacol Ther. 2016;44(10):1039\u201350.","journal-title":"Aliment Pharmacol Ther"},{"issue":"21","key":"9622_CR165","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.3748\/wjg.14.3313","volume":"14","author":"A Crosignani","year":"2008","unstructured":"Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. \u201cClinical features and management of primary biliary cirrhosis,\u201d (in eng). World J Gastroenterol. 2008;14(21):3313\u201327.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9622_CR166","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. \u201cPrimary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2009;50(1):291\u2013308.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"9622_CR167","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers U. \u201cDrug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis,\u201d (in eng). Nat Clin Pract Gastroenterol Hepatol. 2006;3(6):318\u201328.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"9622_CR168","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U, Trauner M, Jansen P, Poupon R. \u201cNew paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond,\u201d (in eng). J Hepatol. 2015;62(1 Suppl):S25-37.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"9622_CR169","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/S2210-7401(12)70015-3","volume":"36","author":"R Poupon","year":"2012","unstructured":"Poupon R. \u201cUrsodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action,\u201d (in eng). Clin Res Hepatol Gastroenterol. 2012;36(Suppl 1):S3-12.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"9622_CR170","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","volume":"129","author":"J Kondrackiene","year":"2005","unstructured":"Kondrackiene J, Beuers U, Kupcinskas L. \u201cEfficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy,\u201d (in eng). Gastroenterology. 2005;129(3):894\u2013901.","journal-title":"Gastroenterology"},{"issue":"6","key":"9622_CR171","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","volume":"143","author":"Y Bacq","year":"2012","unstructured":"Bacq Y, Sentilhes L, Reyes HB, et al. \u201cEfficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis,\u201d (in eng). Gastroenterology. 2012;143(6):1492\u2013501.","journal-title":"Gastroenterology"},{"issue":"6","key":"9622_CR172","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2014.01.029","volume":"60","author":"PJ Trivedi","year":"2014","unstructured":"Trivedi PJ, Bruns T, Cheung A, et al. \u201cOptimising risk stratification in primary biliary cirrhosis: AST\/platelet ratio index predicts outcome independent of ursodeoxycholic acid response,\u201d (in eng). J Hepatol. 2014;60(6):1249\u201358.","journal-title":"J Hepatol"},{"issue":"7","key":"9622_CR173","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","volume":"149","author":"WJ Lammers","year":"2015","unstructured":"Lammers WJ, Hirschfield GM, Corpechot C, et al. \u201cDevelopment and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy,\u201d (in eng). Gastroenterology. 2015;149(7):1804-12.e4.","journal-title":"Gastroenterology"},{"issue":"12","key":"9622_CR174","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76(12):1221\u20136.","journal-title":"Drugs"},{"issue":"2","key":"9622_CR175","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","volume":"17","author":"AF Gulamhusein","year":"2020","unstructured":"Gulamhusein AF, Hirschfield GM. \u201cPrimary biliary cholangitis: pathogenesis and therapeutic opportunities,\u201d (in eng). Nat Rev Gastroenterol Hepatol. 2020;17(2):93\u2013110.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10266","key":"9622_CR176","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","volume":"396","author":"A Lleo","year":"2020","unstructured":"Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. The Lancet. 2020;396(10266):1915\u201326.","journal-title":"The Lancet"},{"issue":"2","key":"9622_CR177","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","volume":"74","author":"GM Hirschfield","year":"2021","unstructured":"Hirschfield GM, Beuers U, Kupcinskas L, et al. \u201cA placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA,\u201d (in eng). J Hepatol. 2021;74(2):321\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR178","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/hep.27744","volume":"62","author":"NS Ghonem","year":"2015","unstructured":"Ghonem NS, Assis DN, Boyer JL. \u201cFibrates and cholestasis,\u201d (in eng). Hepatology (Baltimore, MD). 2015;62(2):635\u201343.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR179","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","volume":"136","author":"S Kersten","year":"2017","unstructured":"Kersten S, Stienstra R. \u201cThe role and regulation of the peroxisome proliferator activated receptor alpha in human liver,\u201d (in eng). Biochimie. 2017;136:75\u201384.","journal-title":"Biochimie"},{"issue":"6","key":"9622_CR180","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/hep.20705","volume":"41","author":"K Harada","year":"2005","unstructured":"Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. \u201cTh1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2005;41(6):1329\u201338.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"23","key":"9622_CR181","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al. \u201cA placebo-controlled trial of bezafibrate in primary biliary cholangitis,\u201d (in eng). N Engl J Med. 2018;378(23):2171\u201381.","journal-title":"N Engl J Med"},{"issue":"3","key":"9622_CR182","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries E, Bolier R, Goet J, et al. \u201cFibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial,\u201d (in eng). Gastroenterology. 2021;160(3):734-43.e6.","journal-title":"Gastroenterology"},{"issue":"10","key":"9622_CR183","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1007\/s10620-016-4250-y","volume":"61","author":"VS Hegade","year":"2016","unstructured":"Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ. \u201cLong-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score,\u201d (in eng). Dig Dis Sci. 2016;61(10):3037\u201344.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"9622_CR184","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"9","key":"9622_CR185","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"issue":"6","key":"9622_CR186","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/liv.13634","volume":"38","author":"MR Jain","year":"2018","unstructured":"Jain MR, Giri SR, Bhoi B, et al. \u201cDual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models,\u201d (in eng). Liver Int. 2018;38(6):1084\u201394.","journal-title":"Liver Int"},{"issue":"3","key":"9622_CR187","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K, Sato K, Yamazaki Y, et al. \u201cA prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia,\u201d (in eng). Am J Gastroenterol. 2015;110(3):423\u201331.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"9622_CR188","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al. \u201cA placebo-controlled trial of obeticholic acid in primary biliary cholangitis,\u201d (in eng). N Engl J Med. 2016;375(7):631\u201343.","journal-title":"N Engl J Med"},{"key":"9622_CR189","doi-asserted-by":"crossref","unstructured":"Gong Y, Christensen E and Gluud C. \"Azathioprine for primary biliary cirrhosis,\" (in eng). The Cochrane database of systematic reviews. 2007(3):Cd006000.","DOI":"10.1002\/14651858.CD006000"},{"issue":"5","key":"9622_CR190","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/hep.20897","volume":"42","author":"B Combes","year":"2005","unstructured":"Combes B, Emerson SS, Flye NL, et al. \u201cMethotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2005;42(5):1184\u201393.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"9622_CR191","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0168-8278(94)80092-8","volume":"21","author":"PA McCormick","year":"1994","unstructured":"McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. \u201cThalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study,\u201d (in eng). J Hepatol. 1994;21(4):496\u20139.","journal-title":"J Hepatol"},{"issue":"12","key":"9622_CR192","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1046\/j.1365-2036.2000.00869.x","volume":"14","author":"PL Almasio","year":"2000","unstructured":"Almasio PL, Floreani A, Chiaramonte M, et al. \u201cMulticentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis,\u201d (in eng). Aliment Pharmacol Ther. 2000;14(12):1645\u201352.","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"9622_CR193","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","volume":"322","author":"RH Wiesner","year":"1990","unstructured":"Wiesner RH, Ludwig J, Lindor KD, et al. \u201cA controlled trial of cyclosporine in the treatment of primary biliary cirrhosis,\u201d (in eng). N Engl J Med. 1990;322(20):1419\u201324.","journal-title":"N Engl J Med"},{"key":"9622_CR194","doi-asserted-by":"crossref","unstructured":"Treiber G and Malfertheiner P. \"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid,\" (in eng). J Clin Gastroenterol. 2005;39(9):837\u20138; author reply 8.","DOI":"10.1097\/01.mcg.0000177235.36640.21"},{"key":"9622_CR195","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","volume":"68","author":"C Schramm","year":"2018","unstructured":"Schramm C, Hirschfield G, Mason A, et al. Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study. J Hepatol. 2018;68:S103.","journal-title":"J Hepatol"},{"issue":"7","key":"9622_CR196","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/hep4.1193","volume":"2","author":"DJ Erstad","year":"2018","unstructured":"Erstad DJ, Farrar CT, Ghoshal S, et al. \u201cMolecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid x receptor agonist,\u201d (in eng). Hepatology communications. 2018;2(7):821\u201335.","journal-title":"Hepatology communications"},{"issue":"3","key":"9622_CR197","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000371670","volume":"33","author":"SA Kliewer","year":"2015","unstructured":"Kliewer SA, Mangelsdorf DJ. \u201cBile acids as hormones: the FXR-FGF15\/19 pathway,\u201d (in eng). Dig Dis (Basel, Switzerland). 2015;33(3):327\u201331.","journal-title":"Digestive diseases (Basel, Switzerland)"},{"issue":"9","key":"9622_CR198","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep4.1209","volume":"2","author":"MJ Mayo","year":"2018","unstructured":"Mayo MJ, Wigg AJ, Leggett BA, et al. \u201cNGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial,\u201d (in eng). Hepatol Communi. 2018;2(9):1037\u201350.","journal-title":"Hepatology communications"},{"issue":"2\u20133","key":"9622_CR199","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12016-015-8484-9","volume":"48","author":"U Beuers","year":"2015","unstructured":"Beuers U, Gershwin ME. \u201cUnmet challenges in immune-mediated hepatobiliary diseases,\u201d (in eng). Clin Rev Allergy Immunol. 2015;48(2\u20133):127\u201331.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"9622_CR200","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/liv.12354","volume":"34","author":"P Invernizzi","year":"2014","unstructured":"Invernizzi P, Gershwin ME. \u201cNew therapeutics in primary biliary cirrhosis: will there ever be light?,\u201d (in eng). Liver Int. 2014;34(2):167\u201370.","journal-title":"Liver Int"},{"issue":"2","key":"9622_CR201","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.24748","volume":"55","author":"M Tsuda","year":"2012","unstructured":"Tsuda M, Moritoki Y, Lian ZX, et al. \u201cBiochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid,\u201d (in eng). Hepatology (Baltimore, MD). 2012;55(2):512\u201321.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"9622_CR202","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/hep.30099","volume":"70","author":"A Khanna","year":"2019","unstructured":"Khanna A, Jopson L, Howel D, et al. \u201cRituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial,\u201d (in eng). Hepatology (Baltimore, MD). 2019;70(5):1646\u201357.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"20","key":"9622_CR203","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1089\/scd.2013.0500","volume":"23","author":"L Wang","year":"2014","unstructured":"Wang L, Han Q, Chen H, et al. \u201cAllogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis,\u201d (in eng). Stem Cells Dev. 2014;23(20):2482\u20139.","journal-title":"Stem cells and development"},{"issue":"Suppl 1","key":"9622_CR204","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jgh.12029","volume":"28","author":"L Wang","year":"2013","unstructured":"Wang L, Li J, Liu H, et al. \u201cPilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis,\u201d (in eng). J Gastroenterol Hepatol. 2013;28(Suppl 1):85\u201392.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"9622_CR205","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/hep.26067","volume":"57","author":"A Dhirapong","year":"2013","unstructured":"Dhirapong A, Yang GX, Nadler S, et al. \u201cTherapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis,\u201d (in eng). Hepatology (Baltimore, MD). 2013;57(2):708\u201315.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR206","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s10620-013-2920-6","volume":"59","author":"M Sasaki","year":"2014","unstructured":"Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. \u201cChemokine-chemokine receptor CCL2-CCR2 and CX3CL1-CX3CR1 axis may play a role in the aggravated inflammation in primary biliary cirrhosis,\u201d (in eng). Dig Dis Sci. 2014;59(2):358\u201364.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"9622_CR207","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/jpet.118.254268","volume":"369","author":"H Al-Shamma","year":"2019","unstructured":"Al-Shamma H, Lehmann-Bruinsma K, Carroll C, et al. \u201cThe selective sphingosine 1-phosphate receptor modulator etrasimod regulates lymphocyte trafficking and alleviates experimental colitis,\u201d (in eng). J Pharmacol Exp Ther. 2019;369(3):311\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"9622_CR208","doi-asserted-by":"crossref","unstructured":"Sun Q, Zhang W, Zhong W, Sun X and Zhou Z. \"Pharmacological inhibition of NOX4 ameliorates alcohol-induced liver injury in mice through improving oxidative stress and mitochondrial function,\" (in eng). Biochim Biophys Acta Gen-Subj. 2017;1861(1 Pt A):2912\u201321.","DOI":"10.1016\/j.bbagen.2016.09.009"},{"key":"9622_CR209","doi-asserted-by":"crossref","unstructured":"Dalekos G, Invernizzi P, Nevens F, et al. \"GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial.\" J Hepatol. 2019;70(1):e1-e2.","DOI":"10.1016\/S0618-8278(19)30002-7"},{"key":"9622_CR210","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2147\/DDDT.S170518","volume":"12","author":"YB Hu","year":"2018","unstructured":"Hu YB, Liu XY, Zhan W. \u201cFarnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis,\u201d (in eng). Drug Des Dev Ther. 2018;12:2213\u201321.","journal-title":"Drug Des Dev Ther"},{"key":"9622_CR211","doi-asserted-by":"crossref","unstructured":"Smith HT, Das S, Fettiplace J, et al. Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study. Hepatol Commun. 2025;9(3):e0635. Published 2025 Feb 19.","DOI":"10.1097\/HC9.0000000000000635"},{"key":"9622_CR212","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2018.09.010","volume":"95","author":"HD Ma","year":"2018","unstructured":"Ma HD, Zhao ZB, Ma WT, et al. \u201cGut microbiota translocation promotes autoimmune cholangitis,\u201d (in eng). J Autoimmun. 2018;95:47\u201357.","journal-title":"J Autoimmun"},{"key":"9622_CR213","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mam.2017.06.002","volume":"56","author":"SL Long","year":"2017","unstructured":"Long SL, Gahan CGM, Joyce SA. \u201cInteractions between gut bacteria and bile in health and disease,\u201d (in eng). Mol Aspects Med. 2017;56:54\u201365.","journal-title":"Mol Aspects Med"},{"issue":"3","key":"9622_CR214","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","volume":"50","author":"DV Datta","year":"1966","unstructured":"Datta DV, Sherlock S. \u201cCholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis,\u201d (in eng). Gastroenterology. 1966;50(3):323\u201332.","journal-title":"Gastroenterology"},{"issue":"4","key":"9622_CR215","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer AE, van Dijk R, Leckie P, et al. \u201cSerum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions,\u201d (in eng). Hepatology (Baltimore, MD). 2012;56(4):1391\u2013400.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR216","doi-asserted-by":"crossref","unstructured":"Elsayes KM, Oliveira EP, Narra VR, et al. \"MR and MRCP in the evaluation of primary sclerosing cholangitis: current applications and imaging findings,\" (in eng). J Comput Assist Tomogr. 2006;30(3):398\u2013404.","DOI":"10.1097\/00004728-200605000-00009"},{"key":"9622_CR217","doi-asserted-by":"crossref","unstructured":"Seo N, Kim SY, Lee SS, et al. \"Sclerosing cholangitis: clinicopathologic features, imaging spectrum, and systemic approach to differential diagnosis,\" (in eng). Korean J Radiol. 2016;17(1):25\u201338.","DOI":"10.3348\/kjr.2016.17.1.25"},{"issue":"9904","key":"9622_CR218","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. \u201cPrimary sclerosing cholangitis,\u201d (in eng). Lancet (London, England). 2013;382(9904):1587\u201399.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"9622_CR219","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MOG.0000000000000333","volume":"33","author":"WR Takakura","year":"2017","unstructured":"Takakura WR, Tabibian JH, Bowlus CL. \u201cThe evolution of natural history of primary sclerosing cholangitis,\u201d (in eng). Curr Opin Gastroenterol. 2017;33(2):71\u20137.","journal-title":"Curr Opin Gastroenterol"},{"key":"9622_CR220","doi-asserted-by":"crossref","unstructured":"Yimam KK and Bowlus CL. \"Diagnosis and classification of primary sclerosing cholangitis,\" (in eng). Autoimmun Rev. 2014;13(4\u20135):445\u201350.","DOI":"10.1016\/j.autrev.2014.01.040"},{"issue":"3","key":"9622_CR221","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2013.03.015","volume":"59","author":"TH Karlsen","year":"2013","unstructured":"Karlsen TH, Boberg KM. \u201cUpdate on primary sclerosing cholangitis,\u201d (in eng). J Hepatol. 2013;59(3):571\u201382.","journal-title":"J Hepatol"},{"issue":"6","key":"9622_CR222","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.bpg.2011.10.002","volume":"25","author":"KM Boberg","year":"2011","unstructured":"Boberg KM, Lind GE. \u201cPrimary sclerosing cholangitis and malignancy,\u201d (in eng). Best Pract Res Clin Gastroenterol. 2011;25(6):753\u201364.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"9622_CR223","first-page":"117","volume":"185","author":"P Milkiewicz","year":"2011","unstructured":"Milkiewicz P, Wunsch E. \u201cPrimary sclerosing cholangitis,\u201d (in eng). Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2011;185:117\u201333.","journal-title":"Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer"},{"issue":"1","key":"9622_CR224","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12016-019-08764-7","volume":"58","author":"J Song","year":"2020","unstructured":"Song J, Li Y, Bowlus CL, Yang G, Leung PSC, Gershwin ME. \u201cCholangiocarcinoma in patients with primary sclerosing cholangitis (PSC): a comprehensive review,\u201d (in eng). Clin Rev Allergy Immunol. 2020;58(1):134\u201349.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"9622_CR225","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K, Weersma RK, van Erpecum KJ, et al. \u201cPopulation-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis,\u201d (in eng). Hepatology (Baltimore, MD). 2013;58(6):2045\u201355.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR226","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","volume":"102","author":"JJ Tischendorf","year":"2007","unstructured":"Tischendorf JJ, Hecker H, Kr\u00fcger M, Manns MP, Meier PN. \u201cCharacterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study,\u201d (in eng). Am J Gastroenterol. 2007;102(1):107\u201314.","journal-title":"Am J Gastroenterol"},{"key":"9622_CR227","doi-asserted-by":"crossref","unstructured":"Lindor KD, Kowdley KV and  Harrison ME. \"ACG clinical guideline: primary sclerosing cholangitis,\" (in eng). Am J Gastroenterol. 2015;110(5):646\u201359; quiz 60","DOI":"10.1038\/ajg.2015.112"},{"issue":"3","key":"9622_CR228","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00281-009-0167-2","volume":"31","author":"AT Borchers","year":"2009","unstructured":"Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME. \u201cLymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis,\u201d (in eng). Sem Immunopathol. 2009;31(3):309\u201322.","journal-title":"Seminars in immunopathology"},{"issue":"10139","key":"9622_CR229","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, Jones DEJ, Lohse AW, Hudson M. \u201cPrimary sclerosing cholangitis,\u201d (in eng). Lancet (London, England). 2018;391(10139):2547\u201359.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"9622_CR230","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/hep.23564","volume":"51","author":"TH Karlsen","year":"2010","unstructured":"Karlsen TH, Melum E, Franke A. \u201cThe utility of genome-wide association studies in hepatology,\u201d (in eng). Hepatology (Baltimore, MD). 2010;51(5):1833\u201342.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"1","key":"9622_CR231","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","volume":"55","author":"S Hohenester","year":"2012","unstructured":"Hohenester S, Wenniger LM, Paulusma CC, et al. \u201cA biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes,\u201d (in eng). Hepatology (Baltimore, MD). 2012;55(1):173\u201383.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"3\u20135","key":"9622_CR232","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsbmb.2011.06.012","volume":"130","author":"JW Jonker","year":"2012","unstructured":"Jonker JW, Liddle C, Downes M. \u201cFXR and PXR: potential therapeutic targets in cholestasis,\u201d (in eng). J Steroid Biochem Mol Biol. 2012;130(3\u20135):147\u201358.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"9622_CR233","doi-asserted-by":"crossref","unstructured":"Strazzabosco M and Fabris L. \"Functional anatomy of normal bile ducts,\" (in eng). Anat Rec (Hoboken, NJ : 2007). 2008;291(6):653\u201360.","DOI":"10.1002\/ar.20664"},{"issue":"9","key":"9622_CR234","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00535-018-1484-9","volume":"53","author":"H Isayama","year":"2018","unstructured":"Isayama H, Tazuma S, Kokudo N, et al. \u201cClinical guidelines for primary sclerosing cholangitis 2017,\u201d (in eng). J Gastroenterol. 2018;53(9):1006\u201334.","journal-title":"J Gastroenterol"},{"issue":"9","key":"9622_CR235","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","volume":"101","author":"FD Mendes","year":"2006","unstructured":"Mendes FD, Jorgensen R, Keach J, et al. \u201cElevated serum IgG4 concentration in patients with primary sclerosing cholangitis,\u201d (in eng). Am J Gastroenterol. 2006;101(9):2070\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"9622_CR236","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.21685","volume":"45","author":"E Bj\u00f6rnsson","year":"2007","unstructured":"Bj\u00f6rnsson E, Chari ST, Smyrk TC, Lindor K. \u201cImmunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature,\u201d (in eng). Hepatology (Baltimore, MD). 2007;45(6):1547\u201354.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"25","key":"9622_CR237","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.3748\/wjg.14.3948","volume":"14","author":"T Kamisawa","year":"2008","unstructured":"Kamisawa T, Okamoto A. \u201cIgG4-related sclerosing disease,\u201d (in eng). World J Gastroenterol. 2008;14(25):3948\u201355.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"9622_CR238","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/gut.21.10.870","volume":"21","author":"RW Chapman","year":"1980","unstructured":"Chapman RW, Arborgh BA, Rhodes JM, et al. \u201cPrimary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology,\u201d (in eng). Gut.1980;21(10):870\u20137.","journal-title":"Gut"},{"issue":"14","key":"9622_CR239","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJM199504063321406","volume":"332","author":"YM Lee","year":"1995","unstructured":"Lee YM, Kaplan MM. \u201cPrimary sclerosing cholangitis,\u201d (in eng). N Engl J Med. 1995;332(14):924\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"9622_CR240","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/hep.1840100406","volume":"10","author":"RH Wiesner","year":"1989","unstructured":"Wiesner RH, Grambsch PM, Dickson ER, et al. \u201cPrimary sclerosing cholangitis: natural history, prognostic factors and survival analysis,\u201d (in eng). Hepatology (Baltimore, MD). 1989;10(4):430\u20136.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR241","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo P, Peter JB, Gershwin ME, et al. \u201cSerum autoantibodies in patients with primary sclerosing cholangitis,\u201d (in eng). J Hepatol. 2000;32(2):182\u20137.","journal-title":"J Hepatol"},{"issue":"5","key":"9622_CR242","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/gut.33.5.657","volume":"33","author":"F Seibold","year":"1992","unstructured":"Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH. \u201cClinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis,\u201d (in eng). Gut. 1992;33(5):657\u201362.","journal-title":"Gut"},{"issue":"24","key":"9622_CR243","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.3748\/wjg.14.3781","volume":"14","author":"JR Hov","year":"2008","unstructured":"Hov JR, Boberg KM, Karlsen TH. \u201cAutoantibodies in primary sclerosing cholangitis,\u201d (in eng). World J Gastroenterol. 2008;14(24):3781\u201391.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"9622_CR244","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104231","volume":"64","author":"A Waldthaler","year":"2021","unstructured":"Waldthaler A, Schramm C, Bergquist A. Present and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis. Eur J Med Genet. 2021;64(6): 104231.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"9622_CR245","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5946\/ce.2020.019-IDEN","volume":"54","author":"P Bhat","year":"2021","unstructured":"Bhat P, Aabakken L. Role of endoscopy in primary sclerosing cholangitis. Clin Endosc. 2021;54(2):193\u2013201.","journal-title":"Clin Endosc"},{"issue":"8","key":"9622_CR246","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM, et al. \u201cBritish society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis,\u201d (in eng). Gut. 2019;68(8):1356\u201378.","journal-title":"Gut"},{"issue":"5","key":"9622_CR247","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1572-0241.2003.07401.x","volume":"98","author":"KW Burak","year":"2003","unstructured":"Burak KW, Angulo P, Lindor KD. \u201cIs there a role for liver biopsy in primary sclerosing cholangitis?,\u201d (in eng). Am J Gastroenterol. 2003;98(5):1155\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9622_CR248","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","volume":"134","author":"E Bj\u00f6rnsson","year":"2008","unstructured":"Bj\u00f6rnsson E, Olsson R, Bergquist A, et al. \u201cThe natural history of small-duct primary sclerosing cholangitis,\u201d (in eng). Gastroenterology. 2008;134(4):975\u201380.","journal-title":"Gastroenterology"},{"key":"9622_CR249","unstructured":"Berdal JE, Ebbesen J and Rydning A. \"[Incidence and prevalence of autoimmune liver diseases],\" (in nor), Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. Insidens og prevalens av autoimmune leverlidelser. 1998;118(29):4517\u20139"},{"issue":"3","key":"9622_CR250","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","volume":"99","author":"E Bj\u00f6rnsson","year":"2004","unstructured":"Bj\u00f6rnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R. \u201cDominant strictures in patients with primary sclerosing cholangitis,\u201d (in eng). Am J Gastroenterol. 2004;99(3):502\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"9622_CR251","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1055\/s-2006-933564","volume":"26","author":"A Stiehl","year":"2006","unstructured":"Stiehl A. \u201cPrimary sclerosing cholangitis: the role of endoscopic therapy,\u201d (in eng). Semin Liver Dis. 2006;26(1):62\u20138.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"9622_CR252","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11894-006-0011-y","volume":"8","author":"GK Johnson","year":"2006","unstructured":"Johnson GK, Saeian K, Geenen JE. \u201cPrimary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation,\u201d (in eng). Curr Gastroenterol Rep. 2006;8(2):147\u201355.","journal-title":"Curr Gastroenterol Rep"},{"key":"9622_CR253","doi-asserted-by":"crossref","unstructured":"Johnson GK, Geenen JE, Venu RP, Schmalz MJ and Hogan WJ. \"Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment,\" (in eng).\u00a0Gastrointes Endosc. 1991;37(1):38\u201343.","DOI":"10.1016\/S0016-5107(91)70618-4"},{"issue":"3","key":"9622_CR254","first-page":"661","volume":"21","author":"JG Lee","year":"1995","unstructured":"Lee JG, Schutz SM, England RE, Leung JW, Cotton PB. \u201cEndoscopic therapy of sclerosing cholangitis,\u201d (in eng). Hepatology (Baltimore, MD). 1995;21(3):661\u20137.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"9622_CR255","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1572-0241.2001.03690.x","volume":"96","author":"M Kaya","year":"2001","unstructured":"Kaya M, Petersen BT, Angulo P, et al. \u201cBalloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis,\u201d (in eng). Am J Gastroenterol. 2001;96(4):1059\u201366.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"9622_CR256","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A, et al. \u201cDiagnosis and management of primary sclerosing cholangitis,\u201d (in eng). Hepatology (Baltimore, MD). 2010;51(2):660\u201378.","journal-title":"Hepatology (Baltimore, MD)"},{"key":"9622_CR257","unstructured":"Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and european association for the study of the liver (EASL) clinical guideline, in eng).\u00a0J Hepatol. 2017;66(6):1265\u201381."},{"issue":"2","key":"9622_CR258","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.gie.2014.06.030","volume":"81","author":"U Navaneethan","year":"2015","unstructured":"Navaneethan U, Jegadeesan R, Nayak S, et al. \u201cERCP-related adverse events in patients with primary sclerosing cholangitis,\u201d (in eng). Gastrointest Endosc. 2015;81(2):410\u20139.","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"9622_CR259","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1136\/gut.2007.131730","volume":"57","author":"J Neuberger","year":"2008","unstructured":"Neuberger J, Gimson A, Davies M, et al. \u201cSelection of patients for liver transplantation and allocation of donated livers in the UK,\u201d (in eng). Gut. 2008;57(2):252\u20137.","journal-title":"Gut"},{"issue":"6","key":"9622_CR260","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/j.1600-6143.2011.03969.x","volume":"12","author":"D Goldberg","year":"2012","unstructured":"Goldberg D, Bittermann T, Makar G. \u201cLack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis,\u201d (in eng). Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2012;12(6):1603\u20139.","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"9622_CR261","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: Liver transplantation, (in eng).\u00a0J Hepatol. 2016;64(2):433\u201385.","DOI":"10.1016\/j.jhep.2015.10.006"},{"issue":"1","key":"9622_CR262","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-2006-933565","volume":"26","author":"K Bj\u00f8ro","year":"2006","unstructured":"Bj\u00f8ro K, Brandsaeter B, Foss A, Schrumpf E. \u201cLiver transplantation in primary sclerosing cholangitis,\u201d (in eng). Semin Liver Dis. 2006;26(1):69\u201379.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"9622_CR263","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cld.2015.08.011","volume":"20","author":"V Khungar","year":"2016","unstructured":"Khungar V, Goldberg DS. \u201cLiver transplantation for cholestatic liver diseases in adults,\u201d (in eng). Clin Liver Dis. 2016;20(1):191\u2013203.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"9622_CR264","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/lt.21313","volume":"14","author":"J Campsen","year":"2008","unstructured":"Campsen J, Zimmerman MA, Trotter JF, et al. \u201cClinically recurrent primary sclerosing cholangitis following liver transplantation: a time course,\u201d (in eng). Liver Transplant\u202f: Offi Pub Am Asso Study Liver Dis Int Liver Transplantat Soc. 2008;14(2):181\u20135.","journal-title":"Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society"},{"issue":"3","key":"9622_CR265","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.27074","volume":"60","author":"E Wunsch","year":"2014","unstructured":"Wunsch E, Trottier J, Milkiewicz M, et al. \u201cProspective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis,\u201d (in eng). Hepatology (Baltimore, MD). 2014;60(3):931\u201340.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"10","key":"9622_CR266","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/j.1365-2036.2011.04863.x","volume":"34","author":"MH Imam","year":"2011","unstructured":"Imam MH, Sinakos E, Gossard AA, et al. \u201cHigh-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis,\u201d (in eng). Aliment Pharmacol Ther. 2011;34(10):1185\u201392.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"9622_CR267","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/ajg.2011.156","volume":"106","author":"JE Eaton","year":"2011","unstructured":"Eaton JE, Silveira MG, Pardi DS, et al. \u201cHigh-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis,\u201d (in eng). Am J Gastroenterol. 2011;106(9):1638\u201345.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"9622_CR268","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/hep.28991","volume":"65","author":"M Trauner","year":"2017","unstructured":"Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. \u201cNew therapeutic concepts in bile acid transport and signaling for management of cholestasis,\u201d (in eng). Hepatology (Baltimore, MD). 2017;65(4):1393\u2013404.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR269","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","volume":"130","author":"P Fickert","year":"2006","unstructured":"Fickert P, Wagner M, Marschall HU, et al. \u201c24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice,\u201d (in eng). Gastroenterology. 2006;130(2):465\u201381.","journal-title":"Gastroenterology"},{"issue":"1","key":"9622_CR270","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","volume":"9","author":"PJ Trivedi","year":"2016","unstructured":"Trivedi PJ, Hirschfield GM, Gershwin ME. \u201cObeticholic acid for the treatment of primary biliary cirrhosis,\u201d (in eng). Expert Rev Clin Pharmacol. 2016;9(1):13\u201326.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"9622_CR271","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","volume":"73","author":"KV Kowdley","year":"2020","unstructured":"Kowdley KV, Vuppalanchi R, Levy C, et al. \u201cA randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis,\u201d (in eng). J Hepatol. 2020;73(1):94\u2013101.","journal-title":"J Hepatol"},{"issue":"3","key":"9622_CR272","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, Hameed B, et al. \u201cThe nonsteroidal farnesoid x receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis,\u201d (in eng). Hepatology (Baltimore, MD). 2019;70(3):788\u2013801.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"6","key":"9622_CR273","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","volume":"42","author":"S Lemoinne","year":"2018","unstructured":"Lemoinne S, Pares A, Reig A, et al. \u201cPrimary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience,\u201d (in eng). Clin Res Hepatol Gastroenterol. 2018;42(6):521\u20138.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"9622_CR274","doi-asserted-by":"publisher","first-page":"185","DOI":"10.18097\/pbmc20206603185","volume":"66","author":"EE Saveleva","year":"2020","unstructured":"Saveleva EE, Tyutrina ES, Nakanishi T, Tamai I, Salmina AB. \u201c[The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs],\u201d (in rus). Biomed Khim. 2020;66(3):185\u201395.","journal-title":"Biomeditsinskaia khimiia"},{"issue":"1","key":"9622_CR275","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep.28274","volume":"63","author":"ZW Peng","year":"2016","unstructured":"Peng ZW, Ikenaga N, Liu SB, et al. \u201cIntegrin \u03b1v\u03b26 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis,\u201d (in eng). Hepatology (Baltimore, MD). 2016;63(1):217\u201332.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR276","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1053\/j.gastro.2008.04.009","volume":"135","author":"E Patsenker","year":"2008","unstructured":"Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. \u201cInhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression,\u201d (in eng). Gastroenterology. 2008;135(2):660\u201370.","journal-title":"Gastroenterology"},{"issue":"1","key":"9622_CR277","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.anai.2009.11.003","volume":"104","author":"M Kohan","year":"2010","unstructured":"Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N. \u201cEotaxin-2\/CCL24 and eotaxin-3\/CCL26 exert differential profibrogenic effects on human lung fibroblasts,\u201d (in eng). Ann Allergy Asthma Immunol : Offi Pub Am College Allergy Asthma Immunol. 2010;104(1):66\u201372.","journal-title":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology"},{"issue":"3","key":"9622_CR278","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1619","volume":"5","author":"B Eksteen","year":"2021","unstructured":"Eksteen B, Bowlus CL, Montano-Loza AJ, et al. \u201cEfficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study,\u201d (in eng). Hepatol Commun. 2021;5(3):478\u201390.","journal-title":"Hepatology communications"},{"issue":"21","key":"9622_CR279","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","volume":"26","author":"R Little","year":"2020","unstructured":"Little R, Wine E, Kamath BM, Griffiths AM, Ricciuto A. \u201cGut microbiome in primary sclerosing cholangitis: A review,\u201d (in eng). World J Gastroenterol. 2020;26(21):2768\u201380.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"9622_CR280","doi-asserted-by":"publisher","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","volume":"115","author":"A Shah","year":"2020","unstructured":"Shah A, Macdonald GA, Morrison M, Holtmann G. \u201cTargeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework,\u201d (in eng). Am J Gastroenterol. 2020;115(6):814\u201322.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"9622_CR281","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","volume":"55","author":"AH Ali","year":"2020","unstructured":"Ali AH, Damman J, Shah SB, et al. \u201cOpen-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis,\u201d (in eng). Scand J Gastroenterol. 2020;55(8):941\u201350.","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"9622_CR282","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","volume":"68","author":"LZ Tan","year":"2019","unstructured":"Tan LZ, Reilly CR, Steward-Harrison LC, Balouch F, Muir R, Lewindon PJ. \u201cOral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis,\u201d (in eng). Gut. 2019;68(8):1533\u20135.","journal-title":"Gut"},{"issue":"7","key":"9622_CR283","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","volume":"114","author":"JR Allegretti","year":"2019","unstructured":"Allegretti JR, Kassam Z, Carrellas M, et al. \u201cFecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial,\u201d (in eng). Am J Gastroenterol. 2019;114(7):1071\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"9622_CR284","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","volume":"18","author":"CRH Hedin","year":"2020","unstructured":"Hedin CRH, Sado G, Ndegwa N, et al. \u201cEffects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis,\u201d (in eng). Clin Gastroenterol Hepatol : Offi Clin Prac J Am Gastroenterol Asso. 2020;18(10):2295-304.e2.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"2","key":"9622_CR285","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/apt.14829","volume":"48","author":"CS Tse","year":"2018","unstructured":"Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL. \u201cEffects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease,\u201d (in eng). Aliment Pharmacol Ther. 2018;48(2):190\u20135.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"9622_CR286","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.cgh.2011.03.019","volume":"9","author":"A Bonder","year":"2011","unstructured":"Bonder A, Retana A, Winston DM, Leung J, Kaplan MM. \u201cPrevalence of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome,\u201d (in eng). Clin Gastroenterol Hepatol : Offi Clin Prac J Am Gastroenterol Asso. 2011;9(7):609\u201312.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"2","key":"9622_CR287","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/hep.510280210","volume":"28","author":"AJ Czaja","year":"1998","unstructured":"Czaja AJ. \u201cFrequency and nature of the variant syndromes of autoimmune liver disease,\u201d (in eng). Hepatology (Baltimore, MD). 1998;28(2):360\u20135.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR288","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ajg.2009.616","volume":"105","author":"M Neuhauser","year":"2010","unstructured":"Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. \u201cAutoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis,\u201d (in eng). Am J Gastroenterol. 2010;105(2):345\u201353.","journal-title":"Am J Gastroenterol"},{"key":"9622_CR289","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez Casas OY, D\u00edaz Ram\u00edrez GS, Mar\u00edn Zuluaga JI, et al. \"Autoimmune hepatitis - primary biliary cholangitis overlap syndrome. Long-term outcomes of a retrospective cohort in a university hospital\".Gastroenterol Hepatol. 2018;41(9):544\u201352.","DOI":"10.1016\/j.gastre.2018.11.006"},{"issue":"6","key":"9622_CR290","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/j.1572-0241.2007.01136.x","volume":"102","author":"MG Silveira","year":"2007","unstructured":"Silveira MG, Talwalkar JA, Angulo P, Lindor KD. \u201cOverlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes,\u201d (in eng). Am J Gastroenterol. 2007;102(6):1244\u201350.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"9622_CR291","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cgh.2010.03.004","volume":"8","author":"EM Kuiper","year":"2010","unstructured":"Kuiper EM, Zondervan PE, van Buuren HR. \u201cParis criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome,\u201d (in eng). Clin Gastroenterol Hepatol : Offi Clinical Prac J Am Gastroenterol Asso. 2010;8(6):530\u20134.","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"2","key":"9622_CR292","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.510280203","volume":"28","author":"O Chazouill\u00e8res","year":"1998","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. \u201cPrimary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy,\u201d (in eng). Hepatology (Baltimore, MD). 1998;28(2):296\u2013301.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"9622_CR293","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al. \u201cInternational autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis,\u201d (in eng). J Hepatol. 1999;31(5):929\u201338.","journal-title":"J Hepatol"},{"issue":"2","key":"9622_CR294","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jhep.2005.10.017","volume":"44","author":"O Chazouill\u00e8res","year":"2006","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. \u201cLong term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome,\u201d (in eng). J Hepatol. 2006;44(2):400\u20136.","journal-title":"J Hepatol"},{"issue":"3","key":"9622_CR295","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cld.2018.03.010","volume":"22","author":"U To","year":"2018","unstructured":"To U, Silveira M. \u201cOverlap syndrome of autoimmune hepatitis and primary biliary cholangitis,\u201d (in eng). Clin Liver Dis. 2018;22(3):603\u201311.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"9622_CR296","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/00042737-200406000-00012","volume":"16","author":"L Gheorghe","year":"2004","unstructured":"Gheorghe L, Iacob S, Gheorghe C, et al. \u201cFrequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease,\u201d (in eng). Eur J Gastroenterol Hepatol. 2004;16(6):585\u201392.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"9622_CR297","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2036.2008.03722.x","volume":"28","author":"T Al-Chalabi","year":"2008","unstructured":"Al-Chalabi T, Portmann BC, Bernal W, McFarlane IG, Heneghan MA. \u201cAutoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival,\u201d (in eng). Aliment Pharmacol Ther. 2008;28(2):209\u201320.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"9622_CR298","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/hep.23024","volume":"50","author":"M Lewin","year":"2009","unstructured":"Lewin M, Vilgrain V, Ozenne V, et al. \u201cPrevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study,\u201d (in eng). Hepatology (Baltimore, MD). 2009;50(2):528\u201337.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"9622_CR299","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejim.2008.06.004","volume":"20","author":"R Olsson","year":"2009","unstructured":"Olsson R, Glaumann H, Almer S, et al. \u201cHigh prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis,\u201d (in eng). Eur J Intern Med. 2009;20(2):190\u20136.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"9622_CR300","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2169\/internalmedicine.56.7633","volume":"56","author":"G Igarashi","year":"2017","unstructured":"Igarashi G, Endo T, Mikami K, et al. \u201cTwo cases of primary sclerosing cholangitis overlapping with autoimmune hepatitis in adults,\u201d (in eng). Internal medicine (Tokyo, Japan). 2017;56(5):509\u201315.","journal-title":"Internal medicine (Tokyo, Japan)"},{"issue":"8","key":"9622_CR301","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2017.05.018","volume":"16","author":"M Lian","year":"2017","unstructured":"Lian M, Li B, Xiao X, et al. \u201cComparative clinical characteristics and natural history of three variants of sclerosing cholangitis: IgG4-related SC, PSC\/AIH and PSC alone,\u201d (in eng). Autoimmun Rev. 2017;16(8):875\u201382.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"9622_CR302","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1023\/A:1010620122567","volume":"46","author":"KW Burak","year":"2001","unstructured":"Burak KW, Urbanski SJ, Swain MG. \u201cA case of coexisting primary biliary cirrhosis and primary sclerosing cholangitis: a new overlap of autoimmune liver diseases,\u201d (in eng). Dig Dis Sci. 2001;46(9):2043\u20137.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"9622_CR303","first-page":"432","volume":"47","author":"A Floreani","year":"2015","unstructured":"Floreani A, Motta R, Cazzagon N, et al. \u201cThe overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis,\u201d (in eng). Dig Liver Dis : Offi J Italian Soc Gastroenterol Italian Asso Study Liver. 2015;47(5):432\u20135.","journal-title":"Liver"},{"key":"9622_CR304","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2147\/IJGM.S11201","volume":"3","author":"A Jeevagan","year":"2010","unstructured":"Jeevagan A. \u201cOverlap of primary biliary cirrhosis and primary sclerosing cholangitis - a rare coincidence or a new syndrome,\u201d (in eng). Int J Gen Med. 2010;3:143\u20136.","journal-title":"International journal of general medicine"},{"issue":"10","key":"9622_CR305","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/00042737-200510000-00011","volume":"17","author":"JG Kingham","year":"2005","unstructured":"Kingham JG, Abbasi A. \u201cCo-existence of primary biliary cirrhosis and primary sclerosing cholangitis: a rare overlap syndrome put in perspective,\u201d (in eng). Eur J Gastroenterol Hepatol. 2005;17(10):1077\u201380.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"9622_CR306","doi-asserted-by":"crossref","unstructured":"Mandolesi D, Lenzi A, D'Errico A, Festi D, Bazzoli F and Colecchia A. \"Primary biliary cholangitis-primary sclerosing cholangitis in an evolving overlap syndrome: A case report\".Gastroent Hepatol. 2017;40(10):669\u201371.","DOI":"10.1016\/j.gastrohep.2016.11.010"},{"issue":"6","key":"9622_CR307","first-page":"429","volume":"4","author":"EM Oliveira","year":"2012","unstructured":"Oliveira EM, Oliveira PM, Becker V, et al. \u201cOverlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report,\u201d (in eng). Journal of clinical medicine research. 2012;4(6):429\u201333.","journal-title":"Journal of clinical medicine research"},{"key":"9622_CR308","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2018.54","volume":"5","author":"S Sundaram","year":"2018","unstructured":"Sundaram S, K S, Mazumdar S and Shukla A. \u201cOverlap syndrome between primary biliary cholangitis and primary sclerosing cholangitis,\u201d (in eng). ACG Case Rep J. 2018;5:e54.","journal-title":"ACG case reports journal"},{"key":"9622_CR309","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jcag\/gwy009.195","volume":"1","author":"W Alghamdi","year":"2018","unstructured":"Alghamdi W, Qumosani K. A195 triple overlap syndrome? A rare case of AIH, PBC and PSC overlap. J Canadian Asso Gastroenterol. 2018;1:287.","journal-title":"Journal of the Canadian Association of Gastroenterology"},{"issue":"2","key":"9622_CR310","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00281-018-0715-8","volume":"41","author":"D Schwinge","year":"2019","unstructured":"Schwinge D, Schramm C. Sex-related factors in autoimmune liver diseases. Seminars in immunopathology. 2019;41(2):165\u201375.","journal-title":"Seminars in immunopathology"},{"issue":"5","key":"9622_CR311","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","volume":"22","author":"CA Sabatos-Peyton","year":"2010","unstructured":"Sabatos-Peyton CA, Verhagen J, Wraith DC. \u201cAntigen-specific immunotherapy of autoimmune and allergic diseases,\u201d (in eng). Curr Opin Immunol. 2010;22(5):609\u201315.","journal-title":"Curr Opin Immunol"},{"key":"9622_CR312","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3389\/fimmu.2020.01586","volume":"11","author":"N Richardson","year":"2020","unstructured":"Richardson N, Ng STH, Wraith DC. \u201cAntigen-specific immunotherapy for treatment of autoimmune liver diseases,\u201d (in eng). Front Immunol. 2020;11:1586.","journal-title":"Front Immunol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09622-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09622-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:03:51Z","timestamp":1770192231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09622-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":312,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9622"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09622-9","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study did not involve human or animal subjects, and thus, no ethical approval was required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"67"}}